Growth Investors & VC Firms in France

57 firms in this list, with a median first check of $1M. 2 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
FE FELIX CAPITAL FCACAPAT41 people	88🔒	London, England	GB	Seed–Growth	$1M – $20M	+ Add to CRM
GI Giant Ventures Global Llp CMTSMLWD30 people · Leads rounds	88🔒	London	GB	Pre-Seed–Late Stage	—	+ Add to CRM
IR Iris Capital CGEDIEJN27 people	88🔒	Paris	FR	Seed–Late Stage	$1.1M – $32.4M	+ Add to CRM
BA Balderton Capital ARBLCHDW11 people · Leads rounds	88🔒	London	GB	Seed–Late Stage	$5M – $50M	+ Add to CRM
DA Daphni PLPMAVCT37 people	88🔒	Paris	FR	Seed–Growth	$540K – $6.5M	+ Add to CRM
EL Elaia ACEPFDMR11 people	88🔒	Paris	FR	Seed–Growth	$108K – $1.6M	+ Add to CRM
IS Isai JCADCPFC11 people	88🔒	Paris	FR	Pre-Seed–Late Stage	$108K – $54M	+ Add to CRM
NE Next47 USLAMCMZ23 people	88🔒	Palo Alto	US	Seed–Late Stage	—	+ Add to CRM
CA Cathay Innovation CCCICHCF17 people	88🔒	Paris	FR	Seed–Late Stage	$5M – $40M	+ Add to CRM
KH Kharis Capital LVDGMRAC21 people	88🔒	Luxembourg	LU	Seed–Growth	—	+ Add to CRM
AT Atlantic Bridge Ventures BLECGMHM11 people · Follows rounds	88🔒	Dublin	IE	Seed–Late Stage	$1M – $5M	+ Add to CRM
VE Ventech ACASCCCH10 people	88🔒	Paris	FR	Seed–Growth	$540K – $5.4M	+ Add to CRM
ID IDI Group BPBMOGOG5 people · Follows rounds	88🔒	Paris	FR	Seed–Late Stage	—	+ Add to CRM
AT Atomico NZAHBBCB11 people	88🔒	London	GB	Seed–Late Stage	—	+ Add to CRM
EN ENGIE New Ventures JBCCLRSP6 people	88🔒	Paris	FR	Seed–Late Stage	$1.1M – $5.4M	+ Add to CRM
TR True Global Ventures	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
AT Atlantic Vantage Point ASBFDMFR11 people	88🔒	Paris	FR	Seed–Late Stage	$1M – $20M	+ Add to CRM
CI Citizen Capital LMPOAVJP11 people	88🔒	Paris	FR	Seed–Late Stage	$1.1M – $5.4M	+ Add to CRM
DA Dawn Capital LLP DCEPHOHM11 people	88🔒	London	GB	Series A–Growth	$317.5K – $6.3M	+ Add to CRM
EQ EQT Life Sciences APFVFAJR11 people	88🔒	Amsterdam	NL	Seed–Late Stage	$10.8M – $64.8M	+ Add to CRM
ET ETF Partners PSFBLRRD11 people	88🔒	London	GB	Series A–Growth	$5.4M – $16.2M	+ Add to CRM
EU European Circular Bioeconomy Fund DSMAMBMN11 people	88🔒	Bonn	DE	Growth–Late Stage	$2.7M – $10.8M	+ Add to CRM
EV EV Private Equity EGESGHHT11 people	88🔒	Stavanger	NO	Growth	$5M – $30M	+ Add to CRM
GI Gilde Healthcare AFEDGPHD11 people	88🔒	Utrecht	NL	Seed–Late Stage	$1.1M – $32.4M	+ Add to CRM

FELIX CAPITAL

London, EnglandSeed–Growth$1M – $20M

FCACAPAT41 people

Giant Ventures Global Llp

LondonPre-Seed–Late Stage

CMTSMLWD30 people

Iris Capital

ParisSeed–Late Stage$1.1M – $32.4M

CGEDIEJN27 people

Balderton Capital

LondonSeed–Late Stage$5M – $50M

ARBLCHDW11 people

Daphni

ParisSeed–Growth$540K – $6.5M

PLPMAVCT37 people

Elaia

ParisSeed–Growth$108K – $1.6M

ACEPFDMR11 people

Isai

ParisPre-Seed–Late Stage$108K – $54M

JCADCPFC11 people

Next47

Palo AltoSeed–Late Stage

USLAMCMZ23 people

Cathay Innovation

ParisSeed–Late Stage$5M – $40M

CCCICHCF17 people

Kharis Capital

LuxembourgSeed–Growth

LVDGMRAC21 people

Atlantic Bridge Ventures

DublinSeed–Late Stage$1M – $5M

BLECGMHM11 people

Ventech

ParisSeed–Growth$540K – $5.4M

ACASCCCH10 people

IDI Group

ParisSeed–Late Stage

BPBMOGOG5 people

Atomico

LondonSeed–Late Stage

NZAHBBCB11 people

ENGIE New Ventures

ParisSeed–Late Stage$1.1M – $5.4M

JBCCLRSP6 people

True Global Ventures

San FranciscoSeed–Late Stage

Atlantic Vantage Point

ParisSeed–Late Stage$1M – $20M

ASBFDMFR11 people

Citizen Capital

ParisSeed–Late Stage$1.1M – $5.4M

LMPOAVJP11 people

Dawn Capital LLP

LondonSeries A–Growth$317.5K – $6.3M

DCEPHOHM11 people

EQT Life Sciences

AmsterdamSeed–Late Stage$10.8M – $64.8M

APFVFAJR11 people

ETF Partners

LondonSeries A–Growth$5.4M – $16.2M

PSFBLRRD11 people

European Circular Bioeconomy Fund

BonnGrowth–Late Stage$2.7M – $10.8M

DSMAMBMN11 people

EV Private Equity

StavangerGrowth$5M – $30M

EGESGHHT11 people

Gilde Healthcare

UtrechtSeed–Late Stage$1.1M – $32.4M

AFEDGPHD11 people

Data sourced from public filings and firms' own websites — see our methodology.